Zota Health Care Ltd. · NSE:ZOTA
Zota Health Care — Q4 FY22 Earnings Presentation
29 slides from Zota Health Care's earnings presentation, Jun 10, 2022
Slide 1: Exchange cover letter: Investor Presentation submission to NSE
i-zoto' healthcare ltd. )une L0, 2022 To, The Manager Listing Department, The National Stock Exchange of lndia [imited Exchange Plaza, Band ra Kurla Complex, Bandra (E), Mumbai - 400051 Dear Sir/Madam, Trading Symbol: ZOTA Sub: lnvestor Presentation Ref: Regulation 30 of sEBl (tisting obligations an
Slide 2: Q4FY22 Performance Highlights
Q4FY22 PERFORMANCE HIGHLIGHTS JUNE 2022
Slide 3: Safe Harbour
Safe Harbour This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made except by means of offer
Slide 4: Table of Contents
Table Of Contents 01 RESULT HIGHLIGHTS 02 OPERATIONAL METRICS 03 DAVAINDIA BUSINESS OUTLOOK 04 & STRATEGY 05 FINANCIAL SUMMARY zotahealthcare.com
Slide 5: Q4FY22 - Result Highlights
Q4FY22- Result Highlights zotahealthcare.com
Slide 6: Standalone Quarterly Financial Highlights
Stand Quarterly Financial Highlights Q-o-Q Revenues (₹ Lakhs) Gross Profit (%) Operating Profit (₹ Lakhs) PAT (₹ Lakhs) Q4-FY22 3,175.26 Q4-FY22 26.12% Q4-FY22 36.45 Q4-FY22 34.74 Q3-FY22 3,093.88 Q3-FY22 39.93% Q3-FY22 516.50 Q3-FY22 354.23 Y-o-Y Revenues (₹ Lakhs) Gross Profit (%) Operating Profit
Slide 7: Standalone Annual Financial Highlights
Stand Annual Financial Highlights Y-o-Y Revenues (₹ Lakhs) Gross Profit (%) FY22 13,153.33 FY22 33.45% FY21 10,684.12 FY21 31.35% Operating Profit (₹ Lakhs) PAT (₹ Lakhs) FY22 1,534.95 FY22 1,058.01 FY21 67.56 FY21 -16.24 06 zotahealthcare.com
Slide 8: Revenue Break up – Quarterly
Revenue Break up – Quarterly Domestic Sales Dava India Sales Export Sales (SEZ) 1,501.1 1023.8 1,013.4 1,452.6 910.4 768.7 739.5 650.4 1,282.2 Q4-FY21 Q3-FY22 Q4-FY22 Q4-FY21 Q3-FY22 Q4-FY22 Q3-FY21 Q3-FY22 Q4-FY22 07 zotahealthcare.com
Slide 9: FY Result Highlights
FY- Result Highlights zotahealthcare.com
Slide 10: Standalone Profit & Loss Statement - Quarterly
Stand Profit & Loss Statement - Quarterly Particulars (Rs Lakhs) Q4FY22 Q3FY22 YoY % QoQ % Q4FY21 Export Sales (SEZ) 650.39 739.54 -36% -12% 1,013.4 Dava India Sales 1023.78 910.38 33% 12% 768.7 Domestic Sales 1501.09 1452.56 17% 3% 1,282.2 Revenues from Operations 3,175.26 3,093.88 4% 3% 3,064.26 C
Slide 11: Management Commentary
Management Commentary 01 The Company reported a 02 Exports performance suffered 03 The sales contribution from flattish growth in Revenues in a 12% decline QoQ and 36% new-age business stood at Q4FY22, primarily due to lower YoY, due to prolonged 53% in Q4FY22 as compared export sales. container sho
Slide 12: Management Commentary: Domestic Operations and Exports
Management Commentary DOMESTIC OPERATIONS Domestic Revenues registered EBITDA at ₹ 78.26 PAT stood at ₹ a marginal increase of 6.85% Lakhs for Q4FY22, 40.44 Lakhs for QoQ and a growth of 23.11% backed by strong Q4FY22. YoY at ₹ 2524.87 Lakhs recovery in demand supported by healthy of Prescription Ba
Slide 13: Davaindia Generic Pharmacy
Davaindia Generic Pharmacy zotahealthcare.com
Slide 14: Davaindia Key Figures
Davaindia Key Figures Gross Mercantile Value (GMV) Total GMV of Davaindia Stores stood at 1711 Lakhs during Q4FY22 up 14% QoQ No. of SKU’s New Stores rolled-out 55 1,644 49 51 1,614 1,585 34 1,503 Q1-FY22 Q2-FY22 Q3-FY22 Q4-FY22 Q1-FY22 Q2-FY22 Q3-FY22 Q4-FY22 13 zotahealthcare.com
Slide 15: Davaindia Key Figures: Customers Served and Wallet Spend
zotahealthcare.com 6,41,712 Q4-FY22 5,68,183 Q3-FY22 No. of Customers Served 5,40,924 Q2-FY22 4,73,181 Q1-FY22 4,40,458 Q4-FY21 3,23,395 Q3-FY21 3,52,623 Q2-FY21 Davaindia Key Figures 3,38,415 Q1-FY21 2,75,520 Q4-FY20 267 Q4-FY22 237 Q3-FY22 229 Q2-FY22 Average Wallet Spend 220 Q1-FY22 204 Q4-FY21 2
Slide 16: Davaindia - Generic Pharmacy
Davaindia- Generic Pharmacy During the quarter Davaindia has Davaindia has led the revolution of Davaindia retail pharmacy stores’ catered to the highest-ever number of patients opting for generic medicines focus continues to be chronic ailments customer i.e. 6.42 lakhs against 5.68 against branded
Slide 17: Davaindia - Generic Pharmacy
Davaindia- Generic Pharmacy 16 zotahealthcare.com
Slide 18: Davaindia - COCO Stores
Davaindia- COCO Stores 17 zotahealthcare.com
Slide 19: Operational FOFO Stores
Operational FOFO Stores 497 States Arunachal Pradesh Assam No. of Stores 1 7 OPERATIONAL FOFO STORES AS Bihar 15 ON 31.03.2022 Chhattisgarh 2 Delhi 31 Goa 1 Gujarat 55 Haryana 27 Himachal Pradesh 1 Jammu And Kashmir 2 Jharkhand 7 Karnataka 10 Kerala 16 Madhya Pradesh 68 Maharashtra 50 Meghalaya 1 Od
Slide 20: Operational COCO Stores
Operational COCO Stores 17 State Gujarat Haryana No. of Stores 7 2 OPERATIONAL COCO STORES Maharashtra 4 AS ON 31.03.2022 Rajasthan 3 Delhi 1 Legend Company Owned Company Operated (COCO) Stores 19 Operated by wholly-owned subsidiary zotahealthcare.com Davaindia Health Mart Limited
Slide 21: Management Commentary
Management Commentary Commenting on Q4FY22 financial performance and operational highlights, Management Team of Zota Health Care said, “The Company's performance for Q4FY22 has been significantly affected due to the prolonged supply-chain disruption in our export business. During the quarter under r
Slide 22: Industry Snapshot & Business Strategy
Industry Snapshot & Business Strategy zotahealthcare.com
Slide 23: Retail Generic Medicine Landscape in India
Retail Generic Medicine Landscape in India To achieve the objective of making available quality generic medicines at affordable prices to all, ‘Jan Aushadhi Scheme’ was launched by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India across the county. The sche
Slide 24: Impact of PMBJP
Impact of PMBJP In the financial year (2019-20), PMBJP has achieved sales of ₹258 crores (at MRP), up to 30-11-2019. This has led to savings of approximately ₹1,800 crores of the common citizens of the country. Growth in number of stores Growth in turnover Product basket Price of Janaushadhi medicin
Slide 25: Underpenetrated Generic Medicine Market
Underpenetrated Generic Medicine Market 4 pillars to drive Branded and generic mix of Indian healthcare pharma market (%) Overall India Urban India Rural India 4 As of healthcare 8 6 15 1 Accessibility 2 Affordability 3 Awarness 4 Aliments 92 94 85 • Setting up of new • Higher per capita • Rising li
Slide 26: Financial Summary
Financial Summary zotahealthcare.com
Slide 27: Profit & Loss Statement
Profit & Loss Statement Particulars (INR Lakhs) FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 Income from Operations 5,646.3 6,473.3 7,158.0 7,785.2 8,562.9 9,511.3 10,684.12 13,153.33 Other Income 1.4 7.7 5.6 151.9 154.5 151.3 125.66 164.56 Total Income 5,647.8 6,481.0 7,163.6 7,937.0 8,717.4 9,662.6 10,
Slide 28: Balance Sheet & Key Ratios
Balance Sheet & Key Ratios Particulars (INR Lakhs) FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 Share capital 1,196.9 1,436.3 1,436.3 1,436.3 1,754.3 1,754.3 2,456.0 2456.03 2,516.03 Reserves and Surplus 384.2 395.7 707.8 1,262.0 5,223.4 5,138.2 4,426.9 4,181.2 6,621.4 Non-current liabilities 521.3
Slide 29: Thank You
Thank You Contact Information Mr. Himanshu Zota / Mr. Ashvin Variya "ZOTA HOUSE", 2/896, Hira Modi Street, Sagrampura, Surat-395 002(Gujarat) cszota@zotahealthcare.com www.zotahealthcare.com